亞太藥業(002370.SZ):擬將興亞藥業100%股權轉讓給浙江中清大
格隆匯3月31日丨亞太藥業(002370.SZ)公佈,2025年3月31日,公司與浙江中清大建築工業有限公司(以下簡稱“浙江中清大”或“受讓方”)簽署了《關於紹興興亞藥業有限公司之股權轉讓協議》,將公司持有的紹興興亞藥業有限公司(以下簡稱“興亞藥業”或“標的公司”)100%股權轉讓給浙江中清大。截至股權轉讓協議簽署日,興亞藥業應付公司借款為人民幣4872.89萬元,經各方協商一致,本次交易採用承債式收購的方式,即受讓方本次在受讓標的公司100%股權的同時受讓及承接標的公司應向轉讓方償還的負債4872.89萬元,並按協議約定向轉讓方償還前述負債,即就本次交易,受讓方應向轉讓方支付受讓標的公司100%股權的價款1.26億元,並償還標的公司對亞太藥業的債務4872.89萬元,即受讓方應合計向亞太藥業支付1.75億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.